Twitter | Pretraživanje | |
Jeffrey Cranmer
Executive Editor, . All opinions expressed are my own.
1.253
Tweetovi
367
Pratim
713
Osobe koje vas prate
Tweetovi
Jeffrey Cranmer proslijedio/la je tweet
Scott Gottlieb, MD 10 h
The speed by which made a substantial number of tests kits available to U.S. public health labs in rapid fashion (each of the 200 kits can test 700-800 specimens) shouldn’t be understated. This was an important and impressive achievement by our federal health officials.
Reply Retweet Označi sa "sviđa mi se"
Jeffrey Cranmer proslijedio/la je tweet
steve usdin 10 h
Gilead CEO says remdesivir patent dispute won’t affect access to the drug to treat #2019-nCoV outbreak. WHO says remdesivir most promising treatment.
Reply Retweet Označi sa "sviđa mi se"
Jeffrey Cranmer proslijedio/la je tweet
steve usdin 10 h
FDA Oncology Center of Excellence Dir. Richard Pazdur supports expanded access for unapproved uses of approved drugs. This helps patients get access -- if insurers won't pay for an off-label use, a drug co can give it free under EA.
Reply Retweet Označi sa "sviđa mi se"
Jeffrey Cranmer proslijedio/la je tweet
Elizabeth S. Eaton 11 h
. CEO O’Day says patients will be focus of its response, not patents
Reply Retweet Označi sa "sviđa mi se"
Jeffrey Cranmer 11 h
O'Day reacts to Chinese institutes seeking to patent remdesivir for : 'We will not get in a patent dispute.' via in
Reply Retweet Označi sa "sviđa mi se"
Jeffrey Cranmer 14 h
Odgovor korisniku/ci @BiotechSusan
My girl scout is very happy to exploit your weakness for thin mints.
Reply Retweet Označi sa "sviđa mi se"
Jeffrey Cranmer 15 h
PTAB removes major overhang on by upholding validity of patent for $4B therapy Tecfidera; it's all about aducanumab for now. 's reports:
Reply Retweet Označi sa "sviđa mi se"
Jeffrey Cranmer 15 h
Odgovor korisniku/ci @jeff_cranmer
2/2 “The whole point of expanded access is to provide therapies to patients,” says Pazdur.
Reply Retweet Označi sa "sviđa mi se"
Jeffrey Cranmer 15 h
.'s says he supports authorizing requests for unapproved uses of approved medicines. 's reports:
Reply Retweet Označi sa "sviđa mi se"
Jeffrey Cranmer 18 h
shares up 20% as PTAB rules in favor in Tecfidera IPR case v.
Reply Retweet Označi sa "sviđa mi se"
Jeffrey Cranmer proslijedio/la je tweet
Scott Gottlieb, MD 5. velj
Thailand has 25 confirmed cases, Japan 24, Singapore 24. The has continued to spread with Singapore, Malaysia, and Thailand reporting new infections that weren’t imported from China. They now seem to be suffering sustained local transmission.
Reply Retweet Označi sa "sviđa mi se"
Jeffrey Cranmer 5. velj
Odgovor korisniku/ci @maggiekb1
GWAR!
Reply Retweet Označi sa "sviđa mi se"
Jeffrey Cranmer proslijedio/la je tweet
steve usdin 5. velj
Today: WHO says Gilead’s remdesivir most promising drug for #2019-nCoV. WHO plans master protocol to test multiple therapies. FDA authorizes emergency use Dx. HHS funds Regeneron coronavirus antibody. And more at . No paywall.
Reply Retweet Označi sa "sviđa mi se"
Jeffrey Cranmer 5. velj
.'s Vijay Pande tells 's the firm is investing new $750M fund in “weak AI” -- speeding and scaling up tasks humans can do -- while tech that could enable “strong AI,” which does things humans can’t do, matures.
Reply Retweet Označi sa "sviđa mi se"
Jeffrey Cranmer 5. velj
At least 22 MNCs are sponsoring interventional trials in China, 18 have trial sites in Wuhan, the epicenter of the outbreak. An analysis of cos most active in the region finds Roche could be most affected. via
Reply Retweet Označi sa "sviđa mi se"
Jeffrey Cranmer 5. velj
CEO O'Day: has sense of "urgency" for M&A, seeking “transformative" deals a la , as well as small- to medium-sized bolt-on takeouts. Co also working “night and day” to ramp up manufacturing for therapy via 's
Reply Retweet Označi sa "sviđa mi se"
Jeffrey Cranmer 5. velj
. draft report: 's remdesivir most "promising" candidate to treat , planning for trial under way. says its “investing pretty heavily” in manufacturing of the therapy “to make sure we’re prepared as best as we can” via
Reply Retweet Označi sa "sviđa mi se"
Jeffrey Cranmer proslijedio/la je tweet
Scott Gottlieb, MD 4. velj
Thread: There are now 2 deaths in 146 patients diagnosed with outside China. It’s a case fatality rate of 1.37%. This may be our best estimate to date. The patients include mild disease as well those presenting with pneumonia. It tracks with 2% CFR reported in China.
Reply Retweet Označi sa "sviđa mi se"
Jeffrey Cranmer proslijedio/la je tweet
Scott Gottlieb, MD 4. velj
Great work by to take a key step toward being able to expand testing for to state and local public health labs.
Reply Retweet Označi sa "sviđa mi se"
Jeffrey Cranmer 4. velj
raises $500M in part to pay for takeout of . Price is nearly 16x the cell/gene therapy CDMO's '18 rev of €17.4M - Catalent paid 6x for Paragon last year. Sign of increasing competition for manufacturing capacity in new modalities?
Reply Retweet Označi sa "sviđa mi se"